Semaglutide for PCOS may help some people with higher weight lose weight and have more regular periods. PCOS, short for polycystic ovary syndrome, is a hormone condition that can disrupt periods and blood-sugar regulation. Small studies are encouraging, but semaglutide isn't an established fertility treatment. Pregnancy plans matter before treatment starts, because ovulation, the release of an egg, can return unexpectedly.
What semaglutide for PCOS can and cannot mean
Semaglutide acts like GLP-1, a gut hormone that helps regulate appetite and blood sugar. Its clearest role in PCOS is a weight-management goal. A change in periods may follow, but that isn't the same as treating every part of the condition.
The 2023 International Evidence-based PCOS Guideline says semaglutide may be considered for adults with higher weight alongside changes to food and activity. It applies general weight-management guidance; having PCOS doesn't automatically make a weight-loss prescription appropriate.
Metformin is another medicine used in PCOS. It helps the body respond to insulin, the hormone that moves sugar from blood into cells. The choice depends on the problem being treated: weight, blood sugar, irregular periods or difficulty becoming pregnant.
Ozempic or Wegovy for PCOS: when is it off-label?
As of September 30, 2026, the day this article was written, neither Ozempic nor Wegovy lists PCOS as an indication, meaning an official labeled use. The Ozempic injection label says “Revised: 05/2026.” The Wegovy label says “Revised: 06/2026.”
Prescribing a brand specifically for PCOS is off-label use: using it outside its official label. Someone with PCOS may separately meet Wegovy's weight-management criteria. Compounded semaglutide, a preparation a pharmacy makes for a specific prescription, has no approved label of its own.
PCOS is also transitioning to a new name: PMOS, short for polyendocrine metabolic ovarian syndrome. The Endocrine Society announced the change on May 12, 2026. Both names describe the same condition.
What the semaglutide PCOS weight-loss studies found
The early evidence came from small groups. In Carmina and Longo's 2023 study in Journal of Clinical Medicine, 27 women with PCOS and obesity received semaglutide. Mean weight loss was 7.6 kg after three months. There was no untreated PCOS comparison group.
Only the 21 women who lost more than 5% of their weight continued to six months. The results section reports normal periods in 15 of those 21, about 71%. That describes selected responders, not everyone who started treatment.
Chen and colleagues' 2025 randomized trial in Reproductive Biology and Endocrinology assigned treatment groups by chance and compared metformin alone with metformin plus semaglutide. The trial enrolled 100 women with PCOS and higher weight; 80 completed it. Participants knew which treatment they received. At 16 weeks, mean losses were 6.09 kg with the combination and 2.25 kg with metformin alone.
Periods improved more with the combination. Later, after semaglutide stopped and both groups continued metformin, natural pregnancy rates were 35% versus 15%. That is a finding worth discussing, but it doesn't establish better live-birth outcomes or pregnancy safety during treatment.
What changed in the 2026 evidence?
As of September 30, 2026, the day this article was written, newer studies add evidence on ovulation. They still leave important fertility questions open.
A July 2 study by Carmina and Longo in Journal of Clinical Medicine followed 96 women with higher weight who completed six months of semaglutide. Of 80 who weren't ovulating beforehand, 42, just over half, regained regular cycles with ovulation assessed through hormone blood tests. There was no comparison group, and the study didn't measure pregnancies or live births.
An August 10 conference abstract by Banu and Islam in European Journal of Endocrinology reported a randomized study of 31 women with PCOS and obesity. At 16 weeks, 93.3% receiving semaglutide plus metformin lost at least 5% of their starting weight, versus 43.8% receiving metformin alone. This is an abstract rather than a full trial report; it doesn't report fertility outcomes.
A July 3 review in Frontiers in Endocrinology combined 16 randomized trials involving several GLP-1 medicines. It supported weight-loss effects but didn't assess periods or fertility. An August 17 review in Biomedicines also highlighted small studies and reliance on abstracts. These reviews strengthen the weight-management discussion without settling reproductive care.
Does semaglutide replace metformin or tirzepatide?
The combination trials don't answer whether semaglutide alone is better than metformin. They tested adding semaglutide to it. A prescriber may consider either medicine or a combination, depending on goals and tolerability.
Tirzepatide is another prescription weight-management option. Its own studies and pregnancy precautions are covered in tirzepatide for PCOS. Results for one medicine don't predict results for the other, so the comparison needs an individual review.
Pregnancy and birth control change the decision
More regular periods can mean pregnancy becomes possible sooner than expected. The PCOS guideline calls for effective contraception during GLP-1 treatment when pregnancy is possible, because pregnancy safety information is limited.
The Wegovy label specifies stopping semaglutide at least two months before a planned pregnancy. For weight management, it also calls for discontinuation when pregnancy is recognized. The prescriber plans that transition, including other treatment if diabetes is present. Semaglutide and pregnancy covers planned pregnancy and accidental exposure in more detail.
For birth control, a 2015 study in Journal of Clinical Pharmacology found that weekly semaglutide didn't reduce the amount of combined-pill hormones reaching the blood. Its 43 participants were women past menopause with type 2 diabetes, so it wasn't a pregnancy-rate study.
When the main goal is pregnancy, the treatment discussion changes. The guideline names letrozole, a medicine that helps the ovaries release an egg, as the first medication for infertility caused by absent ovulation. That recommendation applies when there are no other infertility factors.
What a provider reviews before prescribing
The review starts with the treatment goal, weight history, blood-sugar results, current medicines and pregnancy timing. Most semaglutide PCOS studies enrolled people with higher weight; they don't establish the same role for someone at a lower weight.
Nausea, vomiting, diarrhea and constipation are common labeled effects. Persistent severe abdominal pain or vomiting that prevents drinking warrants prompt medical assessment. The labels also cover pancreas and gallbladder problems, dehydration and kidney risks.
Screening includes medullary thyroid carcinoma, a rare thyroid cancer, in the patient or family. It also includes MEN 2, an inherited tumor syndrome. The prescriber sets the actual dose and any changes based on response and side effects.
Where compounded semaglutide fits
Through Promise, semaglutide is dispensed as a compounded medication, which is different from an FDA-approved product: the formulation offered here is not FDA-approved. FDA's compounding questions and answers, updated September 16, 2025, explain the separate review status.
The PCOS studies above used weekly injections. Their results don't establish the same outcomes for a compounded preparation or a different route.
A licensed provider may still prescribe a compounded formulation when appropriate; that decision is between the patient and the doctor. At Promise, a licensed provider reviews every request, and not everyone qualifies.
The plan after treatment matters
Stopping belongs in the discussion before treatment begins. In Jensterle and colleagues' 2024 study in Frontiers in Endocrinology, 25 women with PCOS continued metformin and lifestyle support after semaglutide stopped. Over two years, they regained about one-third of the weight they had lost. Twenty-one remained below their starting weight.
The study had no comparison group, so it can't prove that metformin prevented regain. It does show why follow-up needs to extend beyond the last injection. Weight, blood sugar, periods and pregnancy plans may each need a different next step, agreed with the prescriber.
